Back

HAYA Therapeutics

HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. The company is using its innovative cell-state modifying platform to gain novel insights into the biology of long non-coding RNAs (lncRNAs), the ‘dark genomes’ information processing features and ‘source code’. HAYA’s lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, which is a tissue and cell-specific cardiac lncRNA known to play a role in heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the cell-specific treatment of diseases in other tissues, including the lungs and the microenvironment of solid tumor cancers. Headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at Lilly Gateway Labs, powered by Alexandria, in San Diego, HAYA is led by a world-class team of experts in programmable and precision RNA-targeted therapeutics and is supported by a strong investor consortium. HAYA’s mission is to identify and develop breakthrough disease-modifying therapeutics with the potential for greater efficacy, safety, and accessibility than existing treatments.

17/01/2026
Full time
Senior Scientist II, Data Science (CompBio for Translation and Biomarkers in Cardio-Renal-Metabolics)
HAYA Therapeutics 1066 Epalinges, VD, Switzerland
About HAYA Therapeutics At HAYA Therapeutics, we are revolutionizing RNA-guided genome-targeting therapies to treat fibrosis, heart failure, and other serious chronic diseases associated with aging. Our innovative platform leverages long non-coding RNAs (lncRNAs) - key regulators within the “dark matter” of the genome - to develop first-in-class, highly specific therapies that reprogram disease-driving cell states into a healthy and resilient state, tackling disease at its roots. Following the successful close of our Series A financing, HAYA is well-positioned to advance our pipeline and execute on key scientific and operational milestones, including the advancement of HAYA’s lead program, HTX-001, toward the clinic for the treatment of non-obstructive hypertrophic cardiomyopathy (nHCM). In recognition of our scientific innovation and potential global impact, we have been named one of the 100 early-stage companies selected for the World Economic Forum’s 2025 Technology...